Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling
Clinical Pharmacokinetics · 2024
DOI: 10.1007/s40262-024-01363-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacokinetics, 2024. Verfasst von Krina Mehta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. krinaj@gmail.com. Hauptthemen laut MEDLINE: Diarylquinolines, Models, Biological, Antitubercular Agents, Tuberculosis, Meningeal. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: The use of bedaquiline as a treatment option for drug-resistant tuberculosis meningitis (TBM) is of interest to address the increased prevalence of resistance to first-line antibiotics. To this end, we describe a whole-body physiologically based pharmacokinetic (PBPK) model for bedaquiline to predict central nervous system (CNS) exposure. METHODS: A whole-body PBPK model was developed for bedaquiline and its metabolite, M2. The model included compartments for brain and cerebrospinal fluid (CSF). Model predictions were evaluated by comparison to plasma PK time profiles following different dosing regimens and sparse CSF concentrations data from patients. Simulations were then conducted to compare CNS and lung exposures to plasma exposure at clinically relevant dosing schedules. RESULTS: The model appropriately described the observed plasma and CSF bedaquiline and M2 concentrations from patients with pulmonary tuberculosis (TB). The model predicted a high impact of tissue binding on target site drug concentrations in CNS. Predicted unbound exposures within brain interstitial exposures were comparable with unbound vascular plasma and unbound lung exposures. However, unbound brain intracellular exposures were predicted to be 7% of unbound vascular plasma and unbound lung intracellular exposures. CONCLUSIONS: The whole-body PBPK model for bedaquiline and M2 predicted unbound concentrations in brain to be significantly lower than the unbound concentrations in the lung at clinically relevant doses. Our findings suggest that bedaquiline may result in relatively inferior efficacy against drug-resistant TBM when compared with efficacy against drug-resistant pulmonary TB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands. krinaj@gmail.com.
- esqLabs GmbH, Saterland, Germany.
- Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
- Certara, Canterbury, UK.
ORCID-Profile: Krina Mehta
Zitieren
APA
Mehta, K., Balazki, P., van der Graaf, P. H., Guo, T., & van Hasselt, J. G. C. (2024). Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-024-01363-6
Vancouver
Mehta K, Balazki P, van der Graaf PH, Guo T, van Hasselt JGC. Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling. Clinical Pharmacokinetics. 2024. doi:10.1007/s40262-024-01363-6
BibTeX
@article{Mehta2024,
author = {Mehta, Krina and Balazki, Pavel and van der Graaf, Piet H and Guo, Tingjie and van Hasselt, J G Coen},
title = {Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling},
journal = {Clinical Pharmacokinetics},
year = {2024},
doi = {10.1007/s40262-024-01363-6}
}
EUVIMED